Candel Therapeutics (CADL) Retained Earnings (2020 - 2025)
Candel Therapeutics (CADL) reported Retained Earnings of -$230.4 million for Q4 2025, down 19.87% on a YoY basis from -$287.5 million in Q4 2024, and down 14.69% sequentially from -$200.9 million in Q3 2025.
Candel Therapeutics (CADL) Retained Earnings (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 6 years of Retained Earnings data on file, last reported at -$230.4 million in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings fell 19.87% year-over-year to -$230.4 million; the trailing twelve-month figure through Dec 2025 stood at -$230.4 million (down 19.87% YoY), and the FY2025 full-year result was -$230.4 million, down 19.87% from the prior year.
- Retained Earnings retreated to -$230.4 million in Q4 2025, from -$200.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$65.7 million in Q2 2021 to a low of -$230.4 million in Q4 2025.
- A 5-year average of -$135.0 million and a median of -$125.9 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings tumbled 81.78% in 2021 and decreased 12.78% in 2025, its largest moves.
- Tracing CADL's Retained Earnings over 5 years: stood at -$80.3 million in 2021, then slipped by 23.41% to -$99.1 million in 2022, then tumbled by 38.29% to -$137.0 million in 2023, then slumped by 40.27% to -$192.2 million in 2024, then declined by 19.87% to -$230.4 million in 2025.
- Business Quant data shows CADL's Retained Earnings at -$230.4 million in Q4 2025, -$200.9 million in Q3 2025, and -$189.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Candel Therapeutics | 542.51 Mn | 542.51 Mn | - | -230.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -230.40 Mn |
| Sep 30, 2025 | -200.89 Mn |
| Jun 30, 2025 | -189.62 Mn |
| Mar 31, 2025 | -184.83 Mn |
| Dec 31, 2024 | -192.21 Mn |
| Sep 30, 2024 | -178.13 Mn |
| Jun 30, 2024 | -167.49 Mn |
| Mar 31, 2024 | -145.25 Mn |
| Dec 31, 2023 | -137.03 Mn |
| Sep 30, 2023 | -125.90 Mn |
| Jun 30, 2023 | -117.50 Mn |
| Mar 31, 2023 | -107.90 Mn |
| Dec 31, 2022 | -99.09 Mn |
| Sep 30, 2022 | -94.01 Mn |
| Jun 30, 2022 | -85.30 Mn |
| Mar 31, 2022 | -81.17 Mn |
| Dec 31, 2021 | -80.30 Mn |
| Sep 30, 2021 | -81.89 Mn |
| Jun 30, 2021 | -65.73 Mn |
| Dec 31, 2020 | -44.17 Mn |